⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JAGX News
Jaguar Health, Inc.
Biolojic Design Appoints Roger Waltzman as Chief Medical Officer
globenewswire.com
JAGX
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
accessnewswire.com
JAGX
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
accessnewswire.com
JAGX
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
accessnewswire.com
JAGX
Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream
globenewswire.com
OSRH
SBC
KLXE
GRO
JAGX
XXII
OMEX
CLNN
FFAI
AEM
VOXR
MIGI
NVA
CIA
FUFU
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
globenewswire.com
OSRH
SBC
KLXE
GRO
JAGX
XXII
OMEX
CLNN
FFAI
AEM
VOXR
MIGI
NVA
CIA
FUFU
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
accessnewswire.com
JAGX
Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
accessnewswire.com
JAGX
Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to the Launch of Novel GLP-2 Analogues | DelveInsight
prnewswire.com
IRWD
ZPH
TAK
JAGX
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
accessnewswire.com
JAGX